(12) International Application Status Report

Received at International Bureau: 24 December 2020 (24.12.2020)
Information valid as of: 25 May 2022 (25.05.2022)
Report generated on: 11 September 2023 (11.09.2023)

(10) Publication number:	**(43) Publication date:**	**(26) Publication language:**
WO2021/130638	01 July 2021 (01.07.2021)	English (EN)

(21) Application Number:	**(22) Filing Date:**	**(25) Filing language:**
PCT/IB2020/062229	18 December 2020 (18.12.2020)	English (EN)

(31) Priority number(s):	**(31) Priority date(s):**	**(31) Priority status:**
2019-232938 (JP)	24 December 2019 (24.12.2019)	Priority document received (in compliance with PCT Rule 17.1)
2020-135810 (JP)	11 August 2020 (11.08.2020)	Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61P 31/12 (2006.01); ***A61P 31/14*** (2006.01); ***A61P 31/16*** (2006.01); ***A61P 31/18*** (2006.01); **A61P 35/00** (2006.01); ***A61P 35/02*** (2006.01); ***A61P 35/04*** (2006.01); ***C07D 487/04*** (2006.01); **C07D 519/00** (2006.01); **A61K 31/519** (2006.01); ***A61K 31/5377*** (2006.01); **A61K 31/55** (2006.01); **A61K 31/553** (2006.01); **A61K 31/5415** (2006.01)

(71) Applicant(s):
CARNA BIOSCIENCES, INC. [JP/JP]; 1-5-5, Minatojima-Minamimachi, Chuo-ku Kobe-shi, Hyogo 650-0047 (JP) *(for all designated states)*
GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive Foster City, California 94404 (US) *(for all designated states)*

(72) Inventor(s):
SAWA, Masaaki; c/o Carna Biosciences, Inc. 1-5-5, Minatojima-Minamimachi, Chuo-ku Kobe-shi, Hyogo 650-0047 (JP)
ARAI, Mai; c/o Carna Biosciences, Inc. 1-5-5, Minatojima-Minamimachi, Chuo-ku Kobe-shi, Hyogo 650-0047 (JP)
NAKAI, Ryoko; c/o Carna Biosciences, Inc. 1-5-5, Minatojima-Minamimachi, Chuo-ku Kobe-shi, Hyogo 650-0047 (JP)
MATSUMOTO, Hirokazu; c/o Carna Biosciences, Inc. 1-5-5, Minatojima-Minamimachi, Chuo-ku Kobe-shi, Hyogo 650-0047 (JP)
PUGH, Catherine; 812 Jefferson Court Apt. B San Mateo, California 94401 (US)
HU, Eric; 305 Robinwood Lane Hillsborough, California 94010 (US)
GUERRERO, Juan; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, 94404 (US)
JACOBSEN, Jesse; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
MEDLEY, Jonathan William; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
XU, Jie; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
LAD, Latesh; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
PATEL, Leena; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
GRAUPE, Michael; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
ZHU, Qingming; 208 Siskiyou Court Walnut Creek, California 94598 (US)
HOLMBO, Stephen; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
KOBAYASHI, Tetsuya; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
WATKINS, Will; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
MOAZAMI, Yasamin; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
YEUNG, Suet C.; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
CODELLI, Julian A.; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)
WEAVER, Heath A.; c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 (US)

(74) Agent(s):
Jiangqiong Liu; GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City, California 94404 (US)

(54) Title (EN): DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

(54) Title (FR): COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE

(57) Abstract:

(EN): The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

(FR): La présente invention concerne des composés de modulation de la diacylglycérol kinase, et des compositions pharmaceutiques de ceux-ci, pour le traitement du cancer, comprenant des tumeurs solides, et des infections virales, telles que l'infection par le VIH ou le virus de l'hépatite B. Les composés peuvent être utilisés seuls ou en combinaison avec d'autres agents.

International search report:

Received at International Bureau: 16 February 2021 (16.02.2021) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM